Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 8.6% – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was down 8.6% during mid-day trading on Monday . The stock traded as low as $22.09 and last traded at $21.63. Approximately 49,465 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 242,814 shares. The stock had previously closed at $23.67.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer increased their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Finally, Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $46.83.

Dianthus Therapeutics Trading Down 6.3 %

The firm has a market capitalization of $609.99 million, a P/E ratio of -8.24 and a beta of 1.72. The stock has a 50-day simple moving average of $22.80 and a two-hundred day simple moving average of $25.40.

Institutional Trading of Dianthus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DNTH. Quest Partners LLC increased its position in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares during the period. R Squared Ltd purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter worth approximately $26,000. KLP Kapitalforvaltning AS bought a new position in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $33,000. KBC Group NV purchased a new position in Dianthus Therapeutics during the fourth quarter valued at approximately $35,000. Finally, BNP Paribas Financial Markets purchased a new position in Dianthus Therapeutics during the fourth quarter valued at approximately $59,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.